and cyclophosphamide), sulfasalazine, methotrexate, leflunomide, cyclosporin, anti-tumour necrosis factor agents …

rheumatoid arthritis randomised to receive leflunomide, methotrexate or placebo during a 12-month period. Design and setting …) rating scale values and SG utilities, respectively, for leflunomide, methotrexate and placebo were 67.7 (18.0), 64.8 (18 ….1) and 57.5 (9.2), and 80.2 (22.1), 83.2 (18.0) and 77.0 (20.5). Both leflunomide and methotrexate had higher rating scale …

-case analysis compared monotherapy with etanercept versus a combination therapy with infliximab and methotrexate. Data for the … in an outpatient clinic and the use of methotrexate [NLG12 621 ($US5048) versus NLG269 ($US107) for etanercept]. The … different tumour necrosis factor (TNF) strategies used in the treatment of rheumatoid arthritis (RA): etanercept, a soluble TNF …

RA. Refractory RA is poorly defined but we used the definition of failing at least two DMARDs. Methotrexate, leflunomide …, cyclosporin, glucocorticoids, etanercept and infliximab clinically and statistically significantly improved QOL in patients with …

-to-head. To compare the effectiveness of the biologics etanercept, infliximab, adalimumab and golimumab, the manufacturer … most cost-effective alternative (etanercept). Despite the manufacturer's claim that golimumab was a cost … biologics were considered equally effective, then etanercept, adalimumab and golimumab had almost equal costs and equal QALYs …

sensitivity analyses were conducted on all relevant parameters. Results: Adalimumab, etanercept, adalimumab plus methotrexate and … etanercept versus methotrexate was $US85_100 per QALY. The average lifetime cost across all treatment arms in a woman diagnosed … with methotrexate) as first-line agents versus methotrexate (monotherapy) from a payer perspective. Methods: A Markov model …

the cost utility of five TNF-α inhibitors (in combination with methotrexate [+MTX]) versus MTX monotherapy using …). Abstract: Results:Results: Etanercept+MTX was the most cost-effective treatment strategy in the base-case scenario up to a WTP … etanercept+MTX was a dominant treatment strategy using ACR70 criteria. Abstract: Conclusions:Conclusions: Etanercept+MTX was a …